Bristol Myers to buy drugmaker Karuna for $14 billion
Bristol Myers Squib has today agreed to buy Karuna Therapeutics for $14 billion in cash, gaining a promising experimental schizophrenia drug to power growth as patents on its older therapies expire.
Business
• 22 Dec 23
